Single-scan skeletonization driven by a neighborhood-sequence distance

International audienceShape description is an important step in image analysis. Skeletonization methods are widely used in image analysis as they are a powerful tool to describe a shape. Indeed, a skeleton is a one point wide line centered in the shape which keeps the shape's topology. Commonly, at least two scans of the image are needed for the skeleton computation in the state of art methods of skeletonization. In this work, a single scan is used considering information propagation in order to compute the skeleton. This paper presents also a new single-scan skeletonization using different distances likes d4, d8 and dns

Extraction of bone structure with a single-scan skeletonization driven by distance

International audienceShape description is an important step in image analysis. Skeletonization methods are widely used in image analysis since they are a powerful tool to describe a shape. This paper presents a new single-scan skeletonization using different diskrete distances. The application of this method is the extraction of caracteristics from µCT images in order to estimate the bone state

Path-Based Distance with Varying Weights and Neighborhood Sequences

International audienceThis paper presents a path-based distance where local displacement costs vary both according to the displacement vector and with the travelled distance. The corresponding distance transform algorithm is similar in its form to classical propagation-based algorithms, but the more variable distance increments are either stored in look-up-tables or computed on-the-fly. These distances and distance transform extend neighborhood-sequence distances, chamfer distances and generalized distances based on Minkowski sums. We introduce algorithms to compute, in Z2, a translated version of a neighborhood sequence distance map with a limited number of neighbors, both for periodic and aperiodic sequences. A method to recover the centered distance map from the translated one is also introduced. Overall, the distance transform can be computed with minimal delay, without the need to wait for the whole input image before beginning to provide the result image

Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis

There is growing evidence of activated microglia and inflammatory processes in the cerebral cortex in amyotrophic lateral sclerosis (ALS). Activated microglia is characterized by increased expression of the 18 kDa translocator protein (TSPO) in the brain and may be a useful biomarker of inflammation. In this study, we evaluated neuroinflammation in ALS patients using a radioligand of TSPO, 18F-DPA-714. Ten patients with probable or definite ALS (all right-handed, without dementia, and untreated by riluzole or other medication that might bias the binding on the TSPO), were enrolled prospectively and eight healthy controls matched for age underwent a PET study. Comparison of the distribution volume ratios between both groups were performed using a Mann-Whitney’s test. Significant increase of distribution of volume ratios values corresponding to microglial activation was found in the ALS sample in primary motor, supplementary motor and temporal cortex (p = 0.009, p = 0.001 and p = 0.004, respectively). These results suggested that the cortical uptake of 18F-DPA-714 was increased in ALS patients during the ‘‘time of diagnosis’’ phase of the disease. This finding might improve our understanding of the pathophysiology of ALS and might be a surrogate marker of efficacy of treatment on microglial activation

TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?

Peripheral sterile inflammatory diseases (PSIDs) are a heterogeneous group of disorders that gathers several chronic insults involving the cardiovascular, respiratory, gastrointestinal, or musculoskeletal system and wherein inflammation is the cornerstone of the pathophysiology. In PSID, timely characterization and localization of inflammatory foci are crucial for an adequate care for patients. In brain diseases, in vivo positron emission tomography (PET) exploration of inflammation has matured over the last 20 years, through the development of radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO) as molecular biomarkers of activated microglia. Recently, TSPO has been introduced as a possible molecular target for PSIDs PET imaging, making this protein a potential biomarker to address disease heterogeneity, to assist in patient stratification, and to contribute to predicting treatment response. In this review, we summarized the major research advances recently made in the field of TSPO PET imaging in PSIDs. Promising preliminary results have been reported in bowel, cardiovascular, and rheumatic inflammatory diseases, consolidated by preclinical studies. Limitations of TSPO PET imaging in PSIDs, regarding both its large expression in healthy peripheral tissues, unlike in central nervous system, and the production of peripheral radiolabeled metabolites, are also discussed, regarding their possible consequences on TSPO PET signal’s quantification

The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use

The membrane dopamine transporter (DAT) is involved in a number of brain disorders and its exploration by positron emission tomography (PET) imaging is highly relevant for the early and differential diagnosis, follow-up and treatment assessment of these diseases. A number of carbon-11 and fluor-18 labeled tracers are to date available for this aim, the majority of them being derived from the chemical structure of cocaine. The development of such a tracer, from its conception to its use, is a long process, the expected result being to obtain the best radiopharmaceutical adapted for clinical protocols. In this context, the cocaine derivative (E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4′-tolyl)nortropane, or LBT-999, has passed all the required stages of the development that makes it now a highly relevant imaging tool, particularly in the context of Parkinson's disease. This review describes the different steps of the development of LBT-999 which initially came from its non-fluorinated derivative (E)-N-(3-iodoprop-2-enyl)-2-carbomethoxy-3-(4-methylphenyl) nortropane, or PE2I, because of its high promising properties. [18F]LBT-999 has been extensively characterized in rodent and non-human primate models, in which it demonstrated its capability to explore in vivo the DAT localized at the dopaminergic nerve endings as well as at the mesencephalic cell bodies, in physiological conditions. In lesion-induced rat models of Parkinson's disease, [18F]LBT-999 was able to precisely quantify in vivo the dopaminergic neuron loss, and to assess the beneficial effects of therapeutic approaches such as pharmacological treatment and cell transplantation. Finally recent clinical data demonstrated the efficiency of [18F]LBT-999 in the diagnosis of Parkinson's disease

Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study)

Background: Major depressive disorder (MDD) is a serious public health problem with high lifetime prevalence (4.4–20%) in the general population. The monoamine hypothesis is the most widespread etiological theory of MDD. Also, recent scientific data has emphasized the importance of immuno-inflammatory pathways in the pathophysiology of MDD. The lack of data on the magnitude of brain neuroinflammation in MDD is the main limitation of this inflammatory hypothesis. Our team has previously demonstrated the relevance of [18F] DPA-714 as a neuroinflammation biomarker in humans. We formulated the following hypotheses for the current study: (i) Neuroinflammation in MDD can be measured by [18F] DPA-714; (ii) its levels are associated with clinical severity; (iii) it is accompanied by anatomical and functional alterations within the frontal-subcortical circuits; (iv) it is a marker of treatment resistance.Methods: Depressed patients will be recruited throughout 4 centers (Bordeaux, Montpellier, Tours, and Toulouse) of the French network from 13 expert centers for resistant depression. The patient population will be divided into 3 groups: (i) experimental group—patients with current MDD (n = 20), (ii) remitted depressed group—patients in remission but still being treated (n = 20); and, (iii) control group without any history of MDD (n = 20). The primary objective will be to compare PET data (i.e., distribution pattern of neuroinflammation) between the currently depressed group and the control group. Secondary objectives will be to: (i) compare neuroinflammation across groups (currently depressed group vs. remitted depressed group vs. control group); (ii) correlate neuroinflammation with clinical severity across groups; (iii) correlate neuroinflammation with MRI parameters for structural and functional integrity across groups; (iv) correlate neuroinflammation and peripheral markers of inflammation across groups.Discussion: This study will assess the effects of antidepressants on neuroinflammation as well as its role in the treatment response. It will contribute to clarify the putative relationships between neuroinflammation quantified by brain neuroimaging techniques and peripheral markers of inflammation. Lastly, it is expected to open innovative and promising therapeutic perspectives based on anti-inflammatory strategies for the management of treatment-resistant forms of MDD commonly seen in clinical practice.Clinical trial registration (reference: NCT03314155): https://www.clinicaltrials.gov/ct2/show/NCT03314155?term=neuroinflammation&cond=depression&cntry=FR&rank=

Interest of FDG-PET in the Management of Mantle Cell Lymphoma

FDG-PET changed response assessment and therapy strategy in diffuse large B-cell lymphoma and Hodgkin disease lymphoma. The value of FDG-PET evaluation in MCL has not been extensively studied and a recent expert consensus highlighted the need for more studies addressing this question. Data of the literature show the value of FDG-PET at baseline in patients with MCL, underlining the good sensitivity of this examination for the initial staging of this pathology, but also the potential impact of semi-quantitative analysis in this indication. The determination of SUVmax at diagnosis might indeed provide important prognostic information. Some studies also suggest the potential value of early and end-of-treatment metabolic assessment in MCL, but these results need to be validated in standardized prospective studies. These results also underlie the need to integrate FDG-PET results into MCL treatment strategy to improve disease management in identifying patients who might benefit from more intensive therapy

Molecular imaging of neuroinflammation : preclinical evaluation of a new radiopharmaceutical : cLINDE

La protéine translocatrice 18kDa (TSPO), en reflétant l’activation microgliale et la neuroinflammation, est actuellement reconnue comme un marqueur sensible de la survenue d’événements pathologiques dans le cerveau. Par conséquent, la TSPO est une cible privilégiée pour l’étude des pathologies du cerveau par imagerie moléculaire (TEP/TEMP). Il y a actuellement un manque d’outils efficaces pour explorer la neuroinflammation en TEMP. Notre objectif a donc été d’évaluer un nouveau radiopharmaceutique de forte affinité pour la TSPO, utilisable en TEMP : le CLINDE, dans deux modèles animaux : l’excitotoxicité focale et l’ischémie cérébrale. Dans ces deux modèles, les études ex vivo ont mis en évidence une accumulation préférentielle du [125I]-CLINDE dans les régions cérébrales lésées, riches en cellules microgliales. De plus, nous avons observé une relation quantitative entre l’intensité de la lésion cérébrale et la fixation du radiopharmaceutique. Le CLINDE apparaît donc comme un candidat très prometteur pour l’imagerie TEMP de la neuroinflammation en recherche clinique.The 18kDa Translocator protein (TSPO) is currently the most reliable marker for pathological events in the brain, reflecting microglial activation and neuroinflammation, which are linked to neuronal damage. Thereby, TSPO is a potential target to evaluate neuroinflammatory changes in a variety of brain diseases by molecular imaging (PET/SPECT). To date, there is a lack of effective tool to explore neuroinflammation by SPECT. Our aim was to evaluate a new high-affinity ligand for TSPO SPECT imaging: the CLINDE, in two rodent models: focal excitotoxicity and cerebral ischemia. In both animal models, ex vivo studies highlighted preferential localisation of [125I]-CLINDE accumulation in cerebral area that also expressed activated microglial cells as assessed by immunohistochemical staining. Moreover, we found a quantitative relationship between the intensity of brain damages and radiotracer binding, making CLINDE an attractive radioionidated candidate for imaging neuroinflammation by SPECT in clinical setting

Les Radiopharmaceutiques pour l'imagerie moléculaire de la neuroinflammation

TOURS-BU Sciences Pharmacie (372612104) / SudocSudocFranceF